Compare SKY & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKY | TVTX |
|---|---|---|
| Founded | 2010 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.3B |
| IPO Year | 1994 | 2013 |
| Metric | SKY | TVTX |
|---|---|---|
| Price | $80.93 | $55.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | ★ $98.50 | $40.62 |
| AVG Volume (30 Days) | 561.1K | ★ 1.3M |
| Earning Date | 05-26-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.02 | ★ 92.89 |
| EPS | ★ 3.66 | N/A |
| Revenue | ★ $2,663,639,000.00 | N/A |
| Revenue This Year | $7.79 | $44.76 |
| Revenue Next Year | $3.10 | $35.51 |
| P/E Ratio | $22.81 | ★ N/A |
| Revenue Growth | ★ 7.26 | N/A |
| 52 Week Low | $60.13 | $15.03 |
| 52 Week High | $99.17 | $60.10 |
| Indicator | SKY | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.83 | 48.78 |
| Support Level | $73.38 | $53.93 |
| Resistance Level | $80.85 | $59.89 |
| Average True Range (ATR) | 2.95 | 2.58 |
| MACD | -0.37 | -0.51 |
| Stochastic Oscillator | 21.77 | 30.21 |
Champion Homes Inc is a factory-built housing company in North America. The company is well positioned with an portfolio of manufactured and modular homes, ADUs, park-models and modular buildings for the single-family, multi-family, and other hospitality sectors. In addition to its core home building business, the company provides construction services to install and set-up factory-built homes, operates a factory-direct retail business with 72 retail locations across the United States, and operates Star Fleet Trucking, providing transportation services to the manufactured housing and other industries from several dispatch locations across the United States.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.